These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15081963)

  • 1. The evolution of microarrayed compound screening.
    Hoever M; Zbinden P
    Drug Discov Today; 2004 Apr; 9(8):358-65. PubMed ID: 15081963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and microARCS technologies: identification of ion channel modulators acting on the GABA(A) receptor.
    Joesch C; Guevarra E; Parel SP; Bergner A; Zbinden P; Konrad D; Albrecht H
    J Biomol Screen; 2008 Mar; 13(3):218-28. PubMed ID: 18270364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput techniques for compound characterization and purification.
    Kyranos JN; Cai H; Zhang B; Goetzinger WK
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):719-28. PubMed ID: 11899611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-based chemical screening.
    Carpenter AE
    Nat Chem Biol; 2007 Aug; 3(8):461-5. PubMed ID: 17637778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection criteria for drug-like compounds.
    Muegge I
    Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.
    Dai WG; Pollock-Dove C; Dong LC; Li S
    Adv Drug Deliv Rev; 2008 Mar; 60(6):657-72. PubMed ID: 18222563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of microarrayed compound screening (microARCS) to identify inhibitors of p56lck tyrosine kinase.
    Freiberg G; Wilkins J; David C; Kofron J; Jia Y; Hirst GC; Burns DJ; Warrior U
    J Biomol Screen; 2004 Feb; 9(1):12-21. PubMed ID: 15006144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissimilarity-based approaches to compound acquisition.
    Lajiness M; Watson I
    Curr Opin Chem Biol; 2008 Jun; 12(3):366-71. PubMed ID: 18423415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
    Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
    Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NanoStore: a concept for logistical improvements of compound handling in high-throughput screening.
    Benson N; Boyd HF; Everett JR; Fries J; Gribbon P; Haque N; Henco K; Jessen T; Martin WH; Mathewson TJ; Sharp RE; Spencer RW; Stuhmeier F; Wallace MS; Winkler D
    J Biomol Screen; 2005 Sep; 10(6):573-80. PubMed ID: 16103412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
    Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
    J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-high-throughput screening analysis: an empirical compound prioritization scheme.
    Oprea TI; Bologa CG; Edwards BS; Prossnitz ER; Sklar LA
    J Biomol Screen; 2005 Aug; 10(5):419-26. PubMed ID: 16093551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening Europe 2010: an update about the latest technologies and applications in high-throughput screening.
    Merten CA
    Expert Rev Mol Diagn; 2010 Jul; 10(5):559-63. PubMed ID: 20629504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expediting drug discovery: recent advances in fast medicinal chemistry--optimization of hits and leads.
    Edwards PJ; Allart B; Andrews MJ; Clase JA; Menet C
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):425-44. PubMed ID: 16889227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of uniform-well readouts.
    Josiah S
    Methods Mol Biol; 2009; 486():177-92. PubMed ID: 19347624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP; Horvath CR; Stout SJ; Kenney KL; Ho PI; Zhang JH; Vickers C; Kaushik V; Hubbard B; Wang YK
    Anal Chem; 2007 Nov; 79(21):8207-13. PubMed ID: 17902631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of high-content analysis for compound screening and target selection.
    Rausch O
    IDrugs; 2005 Jul; 8(7):573-7. PubMed ID: 15973566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing screens: how to make your hits a hit.
    Walters WP; Namchuk M
    Nat Rev Drug Discov; 2003 Apr; 2(4):259-66. PubMed ID: 12669025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.